following a full submission:
abrocitinib (Cibinqo®) is accepted for restricted use within NHSScotland.
Indication under review: for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.
SMC restriction: for use in patients who have not responded to, or have lost response to, at least one systemic immunosuppressant therapy, or in whom these are contraindicated or not tolerated.
Four phase III studies demonstrated superiority of abrocitinib in improving signs and symptoms of atopic dermatitis when compared with placebo, as monotherapy or in combination with medicated topical therapies in patients with moderate to severe atopic dermatitis.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
- Medicine name:
- abrocitinib (Cibinqo)
- SMC ID:
Treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Submission type
- Date advice published
- 13 June 2022